Published in J Clin Invest on June 01, 2003
Regulation of bone mass by Wnt signaling. J Clin Invest (2006) 5.59
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood (2009) 3.02
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood (2006) 2.91
Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol (2012) 2.26
The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol (2009) 2.12
The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood (2008) 2.05
Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov (2012) 1.91
Multisite protein kinase A and glycogen synthase kinase 3beta phosphorylation leads to Gli3 ubiquitination by SCFbetaTrCP. Mol Cell Biol (2006) 1.82
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest (2008) 1.81
Smurf1 inhibits osteoblast differentiation and bone formation in vitro and in vivo. J Biol Chem (2003) 1.81
Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood (2007) 1.75
Inhibition of beta-catenin signaling causes defects in postnatal cartilage development. J Cell Sci (2008) 1.67
Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP). Bone (2004) 1.57
Ihh/Gli2 signaling promotes osteoblast differentiation by regulating Runx2 expression and function. Mol Biol Cell (2007) 1.57
The pathogenesis of the bone disease of multiple myeloma. Bone (2008) 1.51
The zinc finger transcription factor Gli2 mediates bone morphogenetic protein 2 expression in osteoblasts in response to hedgehog signaling. Mol Cell Biol (2006) 1.45
Proteasome inhibition by fellutamide B induces nerve growth factor synthesis. Chem Biol (2008) 1.45
Wnt/β-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts. Bone (2012) 1.38
Oxygen tension is an important mediator of the transformation of osteoblasts to osteocytes. J Bone Miner Metab (2007) 1.34
Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood (2009) 1.25
Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options. Turk J Haematol (2014) 1.25
Bone disease in multiple myeloma: pathophysiology and management. Cancer Growth Metastasis (2014) 1.22
Functions of nuclear factor kappaB in bone. Ann N Y Acad Sci (2010) 1.21
Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol (2007) 1.19
Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc Natl Acad Sci U S A (2014) 1.16
Advances in the understanding of myeloma bone disease and tumour growth. Br J Haematol (2010) 1.13
Signal transduction and transcriptional regulation during mesenchymal cell differentiation. J Bone Miner Metab (2008) 1.10
Inhibition of microtubule assembly in osteoblasts stimulates bone morphogenetic protein 2 expression and bone formation through transcription factor Gli2. Mol Cell Biol (2008) 1.10
WNT/beta-catenin signaling is involved in regulation of osteoclast differentiation by human immunodeficiency virus protease inhibitor ritonavir: relationship to human immunodeficiency virus-linked bone mineral loss. Am J Pathol (2008) 1.09
Emerging roles of the host defense peptide LL-37 in human cancer and its potential therapeutic applications. Int J Cancer (2010) 1.09
General transcription factor IIA-gamma increases osteoblast-specific osteocalcin gene expression via activating transcription factor 4 and runt-related transcription factor 2. J Biol Chem (2008) 1.09
Withaferin A: a proteasomal inhibitor promotes healing after injury and exerts anabolic effect on osteoporotic bone. Cell Death Dis (2013) 1.09
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia (2012) 1.07
A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes. Clin Cancer Res (2010) 1.07
CYR61 regulates BMP-2-dependent osteoblast differentiation through the {alpha}v{beta}3 integrin/integrin-linked kinase/ERK pathway. J Biol Chem (2010) 1.05
Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo. Am J Hematol (2009) 1.05
Update in new anabolic therapies for osteoporosis. J Clin Endocrinol Metab (2010) 1.03
Smurf control in bone cells. J Cell Biochem (2010) 1.03
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Natl Compr Canc Netw (2009) 1.03
Control of BMP gene expression by long-range regulatory elements. Cytokine Growth Factor Rev (2009) 1.01
Osthole stimulates osteoblast differentiation and bone formation by activation of beta-catenin-BMP signaling. J Bone Miner Res (2010) 1.00
A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease. Biol Direct (2010) 0.99
Transcriptional regulation of BMP2 expression by the PTH-CREB signaling pathway in osteoblasts. PLoS One (2011) 0.98
Can we change the disease biology of multiple myeloma? Leuk Res (2012) 0.98
Psoralen stimulates osteoblast differentiation through activation of BMP signaling. Biochem Biophys Res Commun (2011) 0.98
Tumor-host cell interactions in the bone disease of myeloma. Bone (2010) 0.96
Activation of the Hh pathway in periosteum-derived mesenchymal stem cells induces bone formation in vivo: implication for postnatal bone repair. Am J Pathol (2010) 0.96
A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica (2010) 0.94
E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis. Cell Death Dis (2013) 0.94
Osteoblastogenesis and tumor growth in myeloma. Leuk Lymphoma (2010) 0.93
Gene profile analysis of osteoblast genes differentially regulated by histone deacetylase inhibitors. BMC Genomics (2007) 0.91
Controlled release strategies for bone, cartilage, and osteochondral engineering--Part I: recapitulation of native tissue healing and variables for the design of delivery systems. Tissue Eng Part B Rev (2013) 0.90
First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro. Eur J Haematol (2010) 0.89
Characterization of Osterix protein stability and physiological role in osteoblast differentiation. PLoS One (2013) 0.87
Proteasome inhibitors and bone disease. Semin Hematol (2012) 0.86
Bone morphogenetic protein signalling is required for the anti-mitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells. Br J Pharmacol (2008) 0.86
Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma. PLoS One (2013) 0.86
Chemical genetics: exploring the role of the proteasome in cell biology using natural products and other small molecule proteasome inhibitors. J Med Chem (2008) 0.85
Bone building with bortezomib. J Clin Invest (2008) 0.84
Probiotics (Bifidobacterium longum) Increase Bone Mass Density and Upregulate Sparc and Bmp-2 Genes in Rats with Bone Loss Resulting from Ovariectomy. Biomed Res Int (2015) 0.81
Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma. Leukemia (2014) 0.81
Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling. Biomed Res Int (2015) 0.80
New treatment modalities in osteoporosis. Endocr Pract (2011) 0.80
Turning Bone Morphogenetic Protein 2 (BMP2) on and off in Mesenchymal Cells. J Cell Biochem (2015) 0.79
Proteasome inhibitors, including curcumin, improve pancreatic β-cell function and insulin sensitivity in diabetic mice. Nutr Diabetes (2016) 0.79
Glycosaminoglycan and growth factor mediated murine calvarial cell proliferation. J Mol Histol (2007) 0.78
Proteasome inhibitors: their effects on arachidonic acid release from cells in culture and arachidonic acid metabolism in rat liver cells. BMC Pharmacol (2004) 0.78
Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma. Sci Rep (2015) 0.78
Say-Meyer syndrome: additional manifestations in a new patient and phenotypic assessment. Childs Nerv Syst (2015) 0.77
Soluble molecules and bone metabolism in multiple myeloma: a review. Clin Cases Miner Bone Metab (2008) 0.77
Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice. PLoS One (2012) 0.77
Effects of proteasome inhibitors on bone cancer. Bonekey Rep (2013) 0.77
Ubiquitin-proteasome system components are upregulated during intestinal regeneration. Genesis (2012) 0.77
Myeloma bone disease. J Bone Miner Res (2009) 0.77
Anabolic actions of Notch on mature bone. Proc Natl Acad Sci U S A (2016) 0.76
Impact of the uremic milieu on the osteogenic potential of mesenchymal stem cells. PLoS One (2015) 0.75
Novel therapeutic targets in myeloma bone disease. Br J Pharmacol (2014) 0.75
E11/Podoplanin Protein Stabilization Through Inhibition of the Proteasome Promotes Osteocyte Differentiation in Murine in Vitro Models. J Cell Physiol (2015) 0.75
Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors. Bone (2013) 0.75
The effects of proteasome inhibitors on bone remodeling in multiple myeloma. Bone (2016) 0.75
Siah2 Mediates Early Events in Commitment to an Adipogenic Pathway. J Biol Chem (2016) 0.75
Ubiquitin E3 ligase Itch negatively regulates osteoblast function by promoting proteasome degradation of osteogenic proteins. Bone Joint Res (2017) 0.75
Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell (1994) 11.73
The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell (1994) 11.62
Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science (1995) 8.58
Stimulation of bone formation in vitro and in rodents by statins. Science (1999) 5.55
Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res (1999) 5.35
Expression cloning of noggin, a new dorsalizing factor localized to the Spemann organizer in Xenopus embryos. Cell (1992) 5.31
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A (1999) 5.28
Proteasome inhibitors: from research tools to drug candidates. Chem Biol (2001) 5.06
Noggin, cartilage morphogenesis, and joint formation in the mammalian skeleton. Science (1998) 4.72
Proteolysis that is inhibited by hedgehog targets Cubitus interruptus protein to the nucleus and converts it to a repressor. Cell (1997) 4.43
Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb. Nature (1998) 4.14
A mouse model of greig cephalopolysyndactyly syndrome: the extra-toesJ mutation contains an intragenic deletion of the Gli3 gene. Nat Genet (1993) 3.99
Sonic Hedgehog-induced activation of the Gli1 promoter is mediated by GLI3. J Biol Chem (1999) 3.25
MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature (1993) 3.18
Hedgehog controls limb development by regulating the activities of distinct transcriptional activator and repressor forms of Cubitus interruptus. Cell (1999) 2.70
Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem (1986) 2.50
Transducing Hedgehog: the story so far. EMBO J (1998) 2.44
Nuclear trafficking of Cubitus interruptus in the transcriptional regulation of Hedgehog target gene expression. Cell (1999) 2.34
Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci U S A (1987) 2.29
Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A (1999) 2.14
Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide alpha',beta'-epoxyketones. Chem Biol (1999) 1.65
Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg Med Chem Lett (1999) 1.54
Eponemycin analogues: syntheses and use as probes of angiogenesis. Bioorg Med Chem (1998) 1.34
Immortalized murine osteoblasts derived from BMP 2-T-antigen expressing transgenic mice. Endocrinology (1996) 1.32
Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res (1999) 1.31
The repressor and activator forms of Cubitus interruptus control Hedgehog target genes through common generic gli-binding sites. Development (2000) 1.28
The effects of cytokines and growth factors on osteoblastic cells. Bone (1995) 1.28
Expression of bone morphogenetic protein messenger RNA in prolonged cultures of fetal rat calvarial cells. J Bone Miner Res (1994) 1.26
Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor. J Mol Biol (2001) 1.25
5-Lipoxygenase metabolites inhibit bone formation in vitro. Endocrinology (1998) 1.15
Systemic administration of acidic fibroblast growth factor (FGF-1) prevents bone loss and increases new bone formation in ovariectomized rats. J Bone Miner Res (1999) 1.14
New insights into the mechanisms and importance of the proteasome in intracellular protein degradation. Biol Chem (1997) 1.08
The cellular chamber of doom. Sci Am (2001) 0.92
Proteasome inhibitors induce apoptosis in growth hormone- and prolactin-secreting rat pituitary tumor cells. J Endocrinol (2002) 0.87
Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell (2001) 15.05
Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med (1999) 10.16
Neurogenesis in the adult is involved in the formation of trace memories. Nature (2001) 8.13
VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J (1999) 6.62
Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest (1998) 5.95
A linkage between DNA markers on the X chromosome and male sexual orientation. Science (1993) 5.82
Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature (1986) 5.68
Stimulation of bone formation in vitro and in rodents by statins. Science (1999) 5.55
Electron microscope heteroduplex studies of sequence relations among bacterial plasmids: identification and mapping of the insertion sequences IS1 and IS2 in F and R plasmids. J Bacteriol (1975) 5.44
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest (1999) 5.30
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A (1999) 5.28
Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature (2000) 4.93
IS2, a genetic element for turn-off and turn-on of gene activity in E. coli. Mol Gen Genet (1974) 4.16
Genome-wide association studies establish that human intelligence is highly heritable and polygenic. Mol Psychiatry (2011) 4.16
Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet (1998) 4.05
Environment and development. Earth system science for global sustainability: grand challenges. Science (2010) 3.92
Tracing B cell development in human germinal centres by molecular analysis of single cells picked from histological sections. EMBO J (1993) 3.85
Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res (1998) 3.79
Copper activates metallothionein gene transcription by altering the conformation of a specific DNA binding protein. Cell (1988) 3.74
A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet (1998) 3.59
Age-dependent impairment of angiogenesis. Circulation (1999) 3.47
Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest (1996) 3.44
Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest (1992) 3.40
Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms. J Med Genet (2003) 3.25
The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci U S A (1997) 3.23
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res (1995) 3.23
Determinants of genital human papillomavirus detection in a US population. J Infect Dis (2001) 3.21
RD-114, baboon, and woolly monkey viral RNA's compared in size and structure. Cell (1976) 3.20
BioMart Central Portal: an open database network for the biological community. Database (Oxford) (2011) 3.03
Imaging the surface of Altair. Science (2007) 3.03
Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology (2000) 2.99
Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med (1974) 2.97
A heteroduplex study of the sequence relationships between the RNAs of M-MSV and M-MLV. Cell (1977) 2.96
Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med (1996) 2.92
Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest (1990) 2.92
Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol (1992) 2.92
Rab11 is required for trans-golgi network-to-plasma membrane transport and a preferential target for GDP dissociation inhibitor. Mol Biol Cell (1998) 2.86
GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell (1996) 2.86
Dendrimer-encapsulated metal nanoparticles: synthesis, characterization, and applications to catalysis. Acc Chem Res (2001) 2.85
Search for a resonance decaying into WZ boson pairs in pp collisions. Phys Rev Lett (2010) 2.83
Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol (1999) 2.83
Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation (1996) 2.79
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol (1999) 2.78
Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell (1992) 2.77
Methylation of histone H3 by coactivator-associated arginine methyltransferase 1. Biochemistry (2001) 2.74
Synergistic enhancement of nuclear receptor function by p160 coactivators and two coactivators with protein methyltransferase activities. J Biol Chem (2001) 2.74
Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat Med (1997) 2.73
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol (1998) 2.73
Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology (1988) 2.60
Electron microscopic heteroduplex studies of sequence relations among plasmids of Escherichia coli: structure of F13 and related F-primes. J Bacteriol (1975) 2.60
Heteroduplex analysis of avian RNA tumor viruses. Proc Natl Acad Sci U S A (1977) 2.59
Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. J Immunol (1987) 2.59
Roles of topoisomerases in maintaining steady-state DNA supercoiling in Escherichia coli. J Biol Chem (2000) 2.58
Establishment of an osteocyte-like cell line, MLO-Y4. J Bone Miner Res (1997) 2.55
The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. Genes Dev (1999) 2.52
Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38delta. J Biol Chem (1997) 2.47
Transcription elongation factor P-TEFb mediates Tat activation of HIV-1 transcription at multiple stages. EMBO J (1998) 2.45
Regulated secretion in platelets: identification of elements of the platelet exocytosis machinery. Blood (1997) 2.44
PRAK, a novel protein kinase regulated by the p38 MAP kinase. EMBO J (1998) 2.44
OATP1B1 polymorphism as a determinant of erythromycin disposition. Clin Pharmacol Ther (2012) 2.43
Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A (1994) 2.41
The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol (2001) 2.41
Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci U S A (2001) 2.39
Dentin matrix protein 1 expression during osteoblastic differentiation, generation of an osteocyte GFP-transgene. Bone (2004) 2.35
High-throughput SNP genotyping by allele-specific PCR with universal energy-transfer-labeled primers. Genome Res (2001) 2.35
The hypercalcemia of cancer. Clinical implications and pathogenic mechanisms. N Engl J Med (1984) 2.33
Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med (1997) 2.31
Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci U S A (1987) 2.29
Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol Cell Biol (1998) 2.29
Absence of cardiolipin in the crd1 null mutant results in decreased mitochondrial membrane potential and reduced mitochondrial function. J Biol Chem (2000) 2.26
Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation (1998) 2.25
Patient selection and outcomes for out-of-hospital births in one family practice. J Fam Pract (1990) 2.22
Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells. Genome Res (2000) 2.21
Primary hyperparathyroidism: changes in the pattern of clinical presentation. Lancet (1980) 2.19
The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev (2001) 2.18
Differential roles for bone morphogenetic protein (BMP) receptor type IB and IA in differentiation and specification of mesenchymal precursor cells to osteoblast and adipocyte lineages. J Cell Biol (1998) 2.17
Validation of the modified Fagerström tolerance questionnaire with salivary cotinine among adolescents. Addict Behav (2000) 2.16
Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol Med (1995) 2.15
The role of water stress in the inactivation of messenger RNA of germinating wheat embryos. Proc Natl Acad Sci U S A (1968) 2.15
X-ray spectra estimation using attenuation measurements from 25 kVp to 18 MV. Med Phys (1999) 2.11
Formulation and physical characterization of large porous particles for inhalation. Pharm Res (1999) 2.10
Bone-resorbing activity in supernatants from lymphoid cell lines. N Engl J Med (1974) 2.08
Efficient interaction of HIV-1 with purified dendritic cells via multiple chemokine coreceptors. J Exp Med (1996) 2.08
The synthesis and properties of the complete complementary DNA transcript of ovalbumin mRNA. Biochemistry (1976) 2.08
Regulation of phosphatidylinositol 3'-kinase by tyrosyl phosphoproteins. Full activation requires occupancy of both SH2 domains in the 85-kDa regulatory subunit. J Biol Chem (1995) 2.06
Effects of interleukin-1 on bone turnover in normal mice. Endocrinology (1989) 2.06
Diagnostic value of the radioisotope erection penogram for vasculogenic impotence. J Urol (1990) 2.05
Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol (2001) 2.05
Infant mortality due to acute respiratory infections: the influence of primary care processes. Health Policy Plan (1997) 2.03
The hypercalcemia of malignancy: pathogenesis and management. Metabolism (1982) 2.01
Reconstitution of the Raf-1-MEK-ERK signal transduction pathway in vitro. Mol Cell Biol (1993) 1.99
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res (1995) 1.97
Sequence and expression of chicken and mouse rsk: homologs of Xenopus laevis ribosomal S6 kinase. Mol Cell Biol (1989) 1.96
Three-dimensional visualization of the rotavirus hemagglutinin structure. Cell (1993) 1.95